Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Asthma I: Introduction

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical phenotyping of asthma patients with elevated sputum eosinophils and low blood eosinophils: a post-hoc analysis of the multicentre ATLANTIS cohort.

EBioMedicine·2026

Same author

Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study.

The Lancet. Respiratory medicine·2026

Same author

Reply to Zhao et al.: Clarifying Structural - Functional Coupling by FeNO Status in VESTIGE.

American journal of respiratory and critical care medicine·2026

Same author

Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials.

American journal of respiratory and critical care medicine·2026

Same author

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

Lancet (London, England)·2026

Same author

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.

The Lancet. Respiratory medicine·2026

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Eosinophilic airway inflammation in COPD.

Shironjit Saha¹, Christopher E Brightling

¹Institute for Lung Health, University Hospitals of Leicester, Leicester, UK.

International Journal of Chronic Obstructive Pulmonary Disease

|December 1, 2007

Summary

Eosinophilic airway inflammation is present in chronic obstructive pulmonary disease (COPD) and may be a therapeutic target. Targeting this inflammation reduced hospital admissions in COPD patients, suggesting potential benefits for disease progression.

More Related Videos

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Related Experiment Videos

Last Updated: Jul 9, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Area of Science:

Pulmonary Medicine
Immunology

Background:

Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality characterized by irreversible airflow obstruction.
Pathophysiology involves emphysema, small airway obliteration, and airway inflammation, primarily by CD8+ lymphocytes, neutrophils, and macrophages.

Purpose of the Study:

To investigate the role and therapeutic potential of eosinophilic airway inflammation in COPD.
To determine if targeting eosinophilic inflammation impacts COPD outcomes.

Main Methods:

Analysis of airway tissue and induced sputum samples from COPD patients.
Evaluation of corticosteroid therapy response based on eosinophil levels.
Assessment of hospital admission rates following sputum eosinophilia normalization.

Main Results:

Eosinophilic airway inflammation is present in 20%-40% of stable COPD patients and increases during exacerbations.
Systemic corticosteroids effectively treat eosinophilic airway inflammation in COPD, with response intensity linked to inflammation severity.
Targeted treatment to normalize sputum eosinophilia reduced hospital admissions in COPD patients.

Conclusions:

Eosinophilic airway inflammation is a significant feature in COPD and a potential therapeutic target.
Modulating eosinophilic inflammation may reduce exacerbations and hospitalizations.
Further research is needed to ascertain if controlling eosinophilic inflammation affects COPD progression and mortality.